Company Overview

Founded in 1992, Wondfo was one of the earliest high-tech biological companies focusing on rapid diagnostics in China. Wondfo was listed on Shenzhen Stock Exchange on June 30, 2015 with a market value of more than RMB 15 billion. The company is dedicated in R&D, production and sales of POCT (point-of-care testing) products (including agents and devices) for IDV (in-vitro diagnosis).


Headquartered in Guangzhou, Wondfo owns 1 research lab here covering nearly 5,000 square meters. Besides, it owns 1 overseas lab in San Diego, 1 branch in Chicago and other 11 overseas offices. Wondfo’s sales network covers more than 120 countries and regions, providing an exciting opportunity for distribution of quality products at a very competitive price.


Currently more than 30% of its staff are holders of master and doctorate degree from prestigious overseas institutions. With its international leading production lines and highly experienced staff, Wondfo’s daily production capacity reaches to 1.5 million test strips. It also provides a number of customized services to professional distributors and partners.

Technical Requirement

  1. Tumor-related screening, medication/therapy guidance, prognostic evaluation, auxiliary diagnostic tools and other technologies or products;

  2. Reproductive health-related products, including screening and diagnosis prior to embryo implantation; prenatal screening and diagnosis; genetic disease diagnosis and risk assessment, and other related technologies and products;

  3. Diagnostic tools or medical devices and consumables related to infectious diseases and pathogenic microorganisms; 

  4. Technologies and products related to prevention, control and diagnosis management as to cardiovascular diseases like hypertension, as well as diabetes and chronic respiratory diseases.

The End
Partner Info
Research and development
Tech Scouting
Tumor screening, companion diagnostics, PGS, PGD, prenatal screening/ diagnostics, infectious disease, pathogenic microorganism, cardiovascular disease, diabetes, chronic respiratory disease, health management
China PR